home / stock / exai / exai short
Short Information | Exscientia Limited (NASDAQ:EXAI)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 2,121,415 |
Total Actual Volume | 9,809,568 |
Short Trends | |
---|---|
Cover Days | 20 |
Short Days | 0 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 106,071 |
Average Short Percentage | 23.10% |
Is there a EXAI Short Squeeze or Breakout about to happen?
See the EXAI Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-19-2024 | $5.19 | $5.14 | $5.27 | $5.05 | 263,761 | 52,412 | 19.87% |
07-18-2024 | $5.4 | $5.12 | $5.4068 | $5.05 | 706,493 | 212,133 | 30.03% |
07-17-2024 | $5.37 | $5.4 | $5.6 | $5.31 | 481,993 | 85,574 | 17.75% |
07-16-2024 | $5.43 | $5.42 | $5.5 | $5.31 | 777,519 | 154,498 | 19.87% |
07-15-2024 | $5.8 | $5.4 | $5.85 | $5.26 | 589,042 | 139,724 | 23.72% |
07-12-2024 | $5.7 | $5.69 | $5.85 | $5.57 | 555,183 | 76,576 | 13.79% |
07-11-2024 | $5.84 | $5.56 | $5.898 | $5.33 | 673,434 | 159,879 | 23.74% |
07-10-2024 | $6.1 | $5.73 | $6.19 | $5.65 | 599,281 | 146,995 | 24.53% |
07-09-2024 | $5.87 | $5.82 | $6.07 | $5.74 | 824,454 | 131,410 | 15.94% |
07-08-2024 | $5.95 | $5.71 | $5.95 | $5.57 | 572,129 | 147,115 | 25.71% |
07-05-2024 | $5.5 | $5.75 | $5.75 | $5.4 | 485,039 | 146,943 | 30.3% |
07-03-2024 | $5.12 | $5.37 | $5.5 | $5.12 | 248,599 | 49,723 | 20% |
07-02-2024 | $5.13 | $5.1 | $5.18 | $5.01 | 302,826 | 94,179 | 31.1% |
07-01-2024 | $5.15 | $5.15 | $5.29 | $5.01 | 320,895 | 100,531 | 31.33% |
06-28-2024 | $5.2 | $5.1 | $5.24 | $5.04 | 321,853 | 63,471 | 19.72% |
06-27-2024 | $5.23 | $5.22 | $5.35 | $5.14 | 257,052 | 55,765 | 21.69% |
06-26-2024 | $5.23 | $5.3 | $5.4 | $5.2 | 258,190 | 57,177 | 22.15% |
06-25-2024 | $5.22 | $5.29 | $5.38 | $5.2 | 251,970 | 84,581 | 33.57% |
06-24-2024 | $5.39 | $5.24 | $5.52 | $5.22 | 350,600 | 112,573 | 32.11% |
06-21-2024 | $5.34 | $5.39 | $5.39 | $5.17 | 969,255 | 50,156 | 5.17% |
News, Short Squeeze, Breakout and More Instantly...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...